Referencias

|  |  |
| --- | --- |
| Albertsen PC, Klotz L, Tombal B, et al. Eur Urol. 2014; 65:565-573 | <http://www.ncbi.nlm.nih.gov/pubmed/24210090> |
| Alibhai SM, Duong-Hua M, Sutradhar R, et al.J Clin Oncol. 2009;27: 3452-3458 | <http://www.ncbi.nlm.nih.gov/pubmed/19506162> |
| Bolla M, Van Tienhoven G, Warde P, et al. Lancet Oncol. 2010;11:1066-1073 | <http://www.ncbi.nlm.nih.gov/pubmed/20933466> |
| D’Amico AV. Chen MH, Renshaw AA, et al. JAMA. 2008 . | <http://www.ncbi.nlm.nih.gov/pubmed/18212313> |
| Efstathiou JA, Bae K, Shipley WU, et al. J Clin Oncol. 2009;27 : 92-99 | <http://www.ncbi.nlm.nih.gov/pubmed/19047297> |
| Efstathiou JA, Bae K, Shipley WU. Et al.Eur Urol. 2008;54;816-823 | <http://www.ncbi.nlm.nih.gov/pubmed/18243498> |
| Firmagon Summary of product characteristics, Dec 4, 2013. |  |
| Firmagon Summary of product characteristics, Dec 4, 2013; 2.US Food & Drug Administration. Available from URL accessed 24th January 2014. | <http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm> |
| Keating NL, O Malley AJ, Freedland SJ, et al. J Natl Cancer Inst. 2010; 102: 39-46 | <http://www.ncbi.nlm.nih.gov/pubmed/19996060> |
| Keating NL, O Malley AJ, Smith MR. J Clin Oncol. 2006; 24: | <http://www.ncbi.nlm.nih.gov/pubmed/16983113> |
| Levine GN, D’Amico AV, Berger P, et al. CA:A Cancer J Clin.2010; 60: 194-201 | <http://www.ncbi.nlm.nih.gov/pubmed/20124400> |
| Moyad MA, Sonnleithner M. Urol Clin N Am. 2004; 31:207-212 | <http://www.ncbi.nlm.nih.gov/pubmed/15123400> |
| Nanda AN. Chen MH. Et al. JAMA.2009;302;866-873 | <http://www.ncbi.nlm.nih.gov/pubmed/19706860> |
| Nguyen PL Je Y, Schutz F, et al. JAMA. 2011; 306:2359-2366 | <http://www.ncbi.nlm.nih.gov/pubmed/22147380> |
| Nguyen PL, Chen M-H, Hoffman KE,et al. BJU Int. 2011; 110:201-205 | <http://www.ncbi.nlm.nih.gov/pubmed/22085233> |
| Punnen S, Cooperberg MR, Sadetsky N, et al. J Clin Oncol. 2011; 29:3510-3516 | <http://www.ncbi.nlm.nih.gov/pubmed/21844498> |
| Roach 3rd M, Bea K, Speight J, et al. J Clin Oncol. 2008;26: 585-591 | <http://www.ncbi.nlm.nih.gov/pubmed/18172188> |
| Saigal CS, Gore JL, Krupski TL, et al. Cancer 2007; 110:1493-1500 | <http://www.ncbi.nlm.nih.gov/pubmed/17657815> |
| SEER base de datos de cuidado médico de 73,196 hombres diagnosticados con cáncer de próstata locorregional de 1992 a 1999 y observados hasta 2001. 36.3% de los hombres recibieron algún agonista LHRH. 3,917 hombres (5.4%) sufrieron infarto al miocardio y 3,301 (4.5%) muerte cardiaca repentina. | <http://seer.cancer.gov/>  Surveillance, Epidemiology and End-Results Program (National Cancer Institute) |
| Studer UE, Whelan P, Alberch W, et al. J Clin Oncol.2006;24: 1868-1876 | <http://www.ncbi.nlm.nih.gov/pubmed/16622261> |
| Tsai HK,D’Amico AV, Sadetsky N, et al. J Natl Cancer Inst. 2007; 99:1516-1524 | <http://www.ncbi.nlm.nih.gov/pubmed/17925537> |
| Van Hemelrijck M, Garmo H, Holmberg L, et al. J Clin Oncol. 2010; 28: 3448-3456 | <http://www.ncbi.nlm.nih.gov/pubmed/20567006> |